News Headlines

  1. Aspire Biopharma Secures Agreement With Microsize For Development Of Novel Sublingual Aspirin 1/29/2026

    Aspire Biopharma Holdings, Inc. ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted, patent-pending drug delivery technology, today announced it has entered into an agreement with Microsize (Quakertown, Pennsylvania), the largest independent North American contract development and manufacturing organization (CDMO) focused on cGMP micronization and particle size engineering.

  2. AstraZeneca Plans To Invest $15B in China Through 2030 To Pioneer The Next-Generation Of Innovative Medicines 1/29/2026

    AstraZeneca today announced $15B investment in China through 2030 to expand medicines manufacturing and R&D. This investment will leverage the country’s scientific excellence, advanced manufacturing, and China-UK healthcare ecosystem collaborations to deliver cutting-edge treatments to patients across China and globally.

  3. Veranova Appoints Jacquelyn Martin As Chief Quality Officer 1/28/2026
  4. Seamless Therapeutics Announces Global Research Collaboration With Lilly To Develop Programmable Recombinase-Based Therapeutics For Hearing Loss 1/28/2026

    Seamless Therapeutics announced today that it has entered into a strategic global research collaboration and licensing agreement with Eli Lilly and Company (“Lilly”) to develop and commercialize programmable recombinase-based treatments targeting hearing loss indications, using Seamless’ proprietary recombinase platform.

  5. WuXi Biologics And Sinorda Biomedicine Enter Strategic Collaboration To Accelerate Development And Manufacturing Of Innovative Bispecific Antibody 1/28/2026

    WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases.

  6. Multiply Labs Announces New Collaboration To Automate Cell Therapy Manufacturing With Robotics 1/27/2026

    Multiply Labs today announced an agreement with AstraZeneca to evaluate the potential for applying GMP-ready robotic systems to commercial-scale cell therapy manufacturing. Multiply Labs is a current leader in autonomous manufacturing technology for advanced therapies.

  7. Halo Pharma To Become A Stand-Alone Drug Product Contract Development And Manufacturing Organization (CDMO) 1/27/2026

    Halo Pharma, a leading CDMO specializing in drug product pharmaceutical development and manufacturing services, will become a stand-alone business as a result of the sale of the Noramco API and associated businesses to Siegfried.

  8. Insilico Medicine And Qilu Pharmaceutical Reach Near $120M Drug Development Collaboration To Accelerate Novel Cardiometabolic Therapies 1/27/2026

    Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, today announced a strategic partnership on innovative drug development, leveraging Insilico's proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management.

  9. Siegfried To Acquire High-Quality Small Molecules Drug Substance Capacity In The US 1/27/2026

    Siegfried, a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, has signed binding agreements with an affiliate of SK Capital Partners to acquire the drug substance business of the Noramco Group and Extractas Bioscience.

  10. Eclipsebio Acquires Terrain Bio To Expand Its End-To-End AI Platform For The Design, Manufacturing, And Validation Of RNA Therapeutics 1/26/2026

    Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics for RNA therapeutics, today announced the acquisition of Terrain Bio, a techbio company specializing in AI/ML RNA design and manufacturing analytics.